Functional Neuromodulation

📍 Minneapolis, United States🗓 Founded 2011👥 7 employees💰 Last funded Nov 2013
Medical Equipment Manufacturing🌐 fxneuromod.com
Website LinkedIn
Functional Neuromodulation Ltd. is investigating the use of deep brain stimulation of the fornix (DBS-f) to drive neural activity and modulate the brain’s memory circuit. The company completed a Phase II multi-center clinical trial of DBS-f in 42 patients with mild probable Alzheimer’s in 2016. Functional Neuromodulation is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with mild Alzheimer’s disease. Investors include Boston Scientific, Genesys Capital Partners, and MS Pace. CAUTION — Investigational device. Limited by Federal law to investigational use
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Functional Neuromodulation?
Functional Neuromodulation has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Functional Neuromodulation last raise funding?
The most recent investment in Functional Neuromodulation recorded on gritt.io was in November 2013.
When was Functional Neuromodulation founded?
Functional Neuromodulation was founded in 2011.
What industry is Functional Neuromodulation in?
Functional Neuromodulation operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Functional Neuromodulation based?
Functional Neuromodulation is headquartered in Minneapolis, United States.